Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 170 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

 		Generalized Myasthenia Gravis Phase3 Australia
Belgium
Canada
China
France
India
Japan
Poland
Romania
South Korea
Spain
Taiwan
United States
View all
 NCT06744920

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

 		Relapsing Remitting Multiple Sclerosis (RRMS) Phase4 Canada NCT06733922

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

 		Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) Phase1, Phase2 France
Germany
Singapore
Spain
View all
 NCT07048197

Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)

 		Pediatric Chronic Heart Failure Japan NCT06659393

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

 		Hidradenitis Suppurativa Phase3 Argentina
Australia
Bulgaria
Canada
China
Colombia
Denmark
Germany
Greece
Italy
Malaysia
Mexico
Poland
Portugal
Slovakia
South Africa
Spain
Switzerland
Taiwan
United States
View all
 NCT06799000

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

 		Sickle Cell Disease Phase3 Colombia
United States 		NCT06439082

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

 		Relapsing Multiple Sclerosis Phase1, Phase2 Australia
France
Germany
Italy
Spain
Switzerland
View all
 NCT06617793

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

 		Polymyalgia Rheumatica Phase3 Argentina
Australia
Belgium
Brazil
Colombia
Czechia
Denmark
France
Germany
Hungary
Israel
Italy
Japan
Mexico
Netherlands
Poland
South Africa
Spain
United Kingdom
United States
View all
 NCT06331312

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

 		Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors United States NCT05868629

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

 		Hidradenitis Suppurativa France NCT06444087